Regeneron Pharmaceuticals Inc (NASDAQ:REGN)
| 823.56 Delayed Data As of 4:00pm ET |  +14.97 / +1.85%Today’s Change | 668.00 Today|||52-Week Range 853.97 | +14.15% Year-to-Date |
Latest REGN News | Press Releases
| Regeneron (REGN), Sanofi's Dupixent Succeeds in 2nd COPD Study Nov 27 / Zacks.com - Paid Partner Content | HRMY vs. REGN: Which Stock Is the Better Value Option? Nov 21 / Zacks.com - Paid Partner Content |
| Kiniksa Pharmaceuticals (KNSA) Up 14.7% YTD: Here's How Nov 24 / Zacks.com - Paid Partner Content | Should You Invest in the iShares Biotechnology ETF (IBB)? Nov 20 / Zacks.com - Paid Partner Content |
| Regeneron (REGN) Stock Rallies 10% YTD: What Lies Ahead? Nov 24 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 808.59 |
| Today’s open | 812.66 |
| Day’s range | 811.95 - 828.80 |
| Volume | 25,023 |
| Average volume (3 months) | 468,932 |
| Market cap | $87.0B |
Data as of 4:00pm ET, 11/30/2023
Growth & Valuation
| Earnings growth (last year) | -46.98% |
| Earnings growth (this year) | -9.37% |
| Earnings growth (next 5 years) | +2.38% |
| Revenue growth (last year) | -24.26% |
| P/E ratio | 23.5 |
| Price/Sales | 6.73 |
| Price/Book | 3.86 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| VRTXVertex Pharmaceutica... | +4.00 | +1.14% |
| ZTSZoetis Inc | +1.02 | +0.58% |
| BMYBristol-Myers Squibb | +0.67 | +1.38% |
| ---- |
Data as of 4:00pm ET, 11/30/2023
Financials
| Next reporting date | February 8, 2024 |
| EPS forecast (this quarter) | $10.21 |
| Annual revenue (last year) | $12.2B |
| Annual profit (last year) | $4.3B |
| Net profit margin | 35.64% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Tarrytown, New York |
Forecasts
